Based in Cambridge, UK, we are making better medicines by continually improving the best antibody technologiesLearn more
Our unique technologies drive our rapid development of effective, human antibodies across our four main therapeutic areas - immuno-oncology, inflammation, haematology and infectious disease.View our pipeline
Join us in developing tomorrow's medicines: we're driven by passion for better healthcare and by compassion to make a difference. Join our experienced and successful team and help us to realise our aims.View our vacancies
Kymab Group Limited appoints Dr Martin Nicklasson as Non-Executive Chair
Kymab has appointed Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group...
Kymab has appointed Dr Arndt Schottelius as its first Executive Vice President Research & Development. Dr Schottelius will lead Kymab's R...
Kymab receives $9m grant from the Bill & Melinda Gates Foundation to fund infectious disease research and development
6 Nov 2017 - 8 Nov 2017 | CityCube Berlin, Berlin, Germany
View event details